PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-50.30%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-42.66%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-107.57%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-114.45%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-158.09%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-158.05%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-158.05%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-85.07%
Negative 10Y revenue/share CAGR while 4997.T stands at 21.03%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-85.07%
Negative 5Y CAGR while 4997.T stands at 21.03%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
29.49%
3Y revenue/share CAGR 1.25-1.5x 4997.T's 21.03%. Bruce Berkowitz might see better product or regional expansions than the competitor.
100.00%
OCF/share CAGR of 100.00% while 4997.T is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
100.00%
OCF/share CAGR of 100.00% while 4997.T is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
100.00%
3Y OCF/share CAGR of 100.00% while 4997.T is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
96.50%
Net income/share CAGR above 1.5x 4997.T's 44.64% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
96.50%
5Y net income/share CAGR above 1.5x 4997.T's 44.64%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
78.40%
3Y net income/share CAGR above 1.5x 4997.T's 44.64%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
150.03%
Equity/share CAGR of 150.03% while 4997.T is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.83%
Firm’s AR is declining while 4997.T shows 1.37%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
71.44%
We show growth while 4997.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
20.47%
Positive asset growth while 4997.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-2.65%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
67.11%
Debt growth far above 4997.T's 59.48%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-100.00%
Our R&D shrinks while 4997.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
No Data
No Data available this quarter, please select a different quarter.